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Is Time Running Out
on Streptokinase?*
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It is now clear that the early restoration of vigorous (Throm-
bolysis in Myocardial Infarction [TIMI] grade 3) flow to the
infarct-related artery during an acute myocardial infarction
(MI) maximizes patient survival and clinical outcome (1,2). In
this issue of the Journal, Steg et al. (3) report that the
reperfusion efficacy of streptokinase (SK), but not tissue-type
plasminogen activator (t-PA), drops considerably when the
interval from the onset of pain to drug administration exceeds
3 h. Although the numbers of patients treated at the later time
points are small, the rapid drop in recanalization rate by SK (to
,20% at 6 h after pain onset) is striking and concerning. These
results are consistent with previous observations (4–8) that
there is progressive resistance of the thrombus to lysis with SK
(as well as anistreplase and urokinase-type plasminogen acti-
vator [u-PA]). Based on data from the TIMI-1 and PAIMS
trials, Sherry and Marder (8) concluded that t-PA and SK are
equivalent in restoring reperfusion during the first 2 h after
onset of symptoms, but thereafter SK is less effective. By their
estimate, t-PA is twice as effective at reperfusion as SK at 4 to
5 h after the onset of pain during an acute MI. This duration
is still well within the 6-h time limit that most physicians in the
United States use for thrombolytic therapy administration.
Why is the thrombus progressively resistant to lysis by SK?
An increased interval may allow for persistent propagation of
the thrombus, so that the total clot burden is increased.
Uncontrolled thrombus extension could be especially signifi-
cant when a large vein graft is the infarct-related vessel. In
addition to quantitative differences, there are qualitative dif-
ferences in the aged thrombus, probably mediated by the
platelet. The platelet alpha-granule contains plasminogen ac-
tivator inhibitor (PAI)-1, the major inhibitor of t-PA and u-PA,
which is released by platelet activation (9). PAI-1 binds to
fibrin, where it is concentrated up to 1,000-fold over the plasma
PAI-1 concentration (10). However, PAI-1 deposition contrib-
utes to only a portion of the platelet-mediated resistance of
thrombi to thrombolysis (11,12). Activated platelets provide
prothrombinase complex activity for the generation of throm-
bin, which may be shielded from inactivation within the
thrombus (13). Platelets are a major source of Factor XIII,
which when activated by thrombin stabilizes fibrin by forming
cross-linked homopolymers and heteropolymers of alpha- and
gamma-chains (14). Factor XIIIa also couples an inhibitor of
plasmin (alpha-2–antiplasmin) directly to the alpha-chain of
fibrin (15). Finally, clot retraction, an energy-consuming pro-
cess involving the platelet glycoprotein (Gp) IIb/IIIa receptor
interacting with fibrin in the extracellular domain and cytoskel-
tal contractile proteins in the cytoplasm, may contribute to
thrombolytic resistance. The retraction or shrinkage of the
thrombus is associated with reduced lysis, reduced t-PA bind-
ing and a more compact clot, with reduced perfusion by
thrombolytic agents (12). The reduced clot permeation could
be especially deleterious for agents that lack fibrin binding
(e.g., SK) because these agents are usually able to diffuse
farther into the unretracted clot than t-PA, the penetration of
which is limited by its fibrin affinity (16).
It is possible that some of the factors that reduce SK efficacy
at longer intervals to treatment reside in the patient rather
than in the thrombus. As myocardial necrosis proceeds, the left
ventricle may have progressively less ability to maintain the
baseline blood pressure. In the most extreme cases, cardio-
genic shock ensues, a condition with a high mortality and poor
response to all thrombolytic agents (17). However, even in less
severe cases, a drop in blood pressure could affect thrombolytic
efficacy. The rate of blood flow through experimental clots in
vitro influences their rate of dissolution by thrombolytic agents
(18), and augmentation of coronary diastolic pressure with
vasopressors (19) or with intraortic pumping (20) increases
coronary thrombolysis in canine models. These considerations
may explain the finding that survival in the Global Utilization
of Streptokinase and TPA for Occluded Coronary Arteries
(GUSTO)-1 trial (for patients treated with both t-PA and SK)
declined when systolic blood pressure was ,120 mm Hg, a
surprisingly high threshold (21). SK infusion, unlike t-PA
therapy, is associated with a significant fall in systolic and
diastolic blood pressure in ;50% of patients (22,23), and up to
30% of patients have a nadir systolic blood pressure
,80 mm Hg (24). Furthermore, hypotension during SK infu-
sion may portend a poorer prognosis (24). Because a longer
interval from onset of pain to treatment increases the rate of
cardiogenic shock (25), it is also likely these patients, as a
group, have a lower blood pressure and reduced ability to
compensate in response to vasodepressing medications. Thus,
it is possible that SK, when administered to a patient who
presents after 3 h of pain with a large infarct and marginal
blood pressure, may cause a pronounced decline in blood
pressure that could adversely affect coronary perfusion pres-
sure and reduce thrombolysis. This hypothesis is consistent
with the finding that lower blood pressure at presentation is
associated with an incremental mortality benefit for patients
who are treated with t-PA versus those treated with SK (26).
The time-dependent decline in reperfusion efficacy with SK
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but not t-PA would be expected to produce a progressive
increase in the relative mortality benefit for t-PA as the time to
treatment lengthens. Instead, this margin narrows. Patients
treated at .6 h in the GUSTO-1 trial had equal survival
statistics with t-PA and SK (27). The most likely explanation
for this finding is that there is little benefit with either
thrombolytic agent as the time to treatment interval increases
(28). Another explanation for this discrepancy is that time to
treatment is a less potent predictor of mortality than previously
thought, with age, blood pressure, heart rate, Killip class and
location of infarction being more closely tied to mortality (21).
Thus, one could argue that the decline in reperfusion efficacy
of SK after the 2- to 3-h interval of equivalence is of little
clinical consequence. However, this is a risky conclusion
because determining the precise onset of pain at the onset of
an MI can be difficult, even during rigorous clinical trials (27).
Patients may have intermittent occlusions causing cyclic pain
syndromes early in the course of a coronary thrombosis. Thus,
when timing is in doubt, and perhaps even when it is not, it
would seem preferable to administer an agent that has no time
limitations to its reperfusion efficacy.
Although thrombolysis will continue to be an important
treatment for acute MI despite the attractiveness of primary
angioplasty, the role of SK as a first-line agent for thrombolytic
therapy is being increasingly challenged. This challenge comes
not only from t-PA, but also from reteplase which was recently
shown (29) to be nearly equivalent to t-PA in benefit, but with
the benefit of a simpler dosing regimen. A variety of other
thrombolytic agents (TNK-t-PA, lanoteplase, staphylokinase)
are in various stages of clinical trials and have potential
advantages over t-PA as well as SK. Because platelets may
have a pivotal role in mediating thrombolytic resistance, trials
using combinations of Gp IIb/IIIa inhibitors with thrombolytic
agents are planned. This combination has shown early promise
(30). Thus, as we enter a new era of genetically modified
plasminogen activators and approach the 65th anniversary of
the discovery of SK (31), the secure position of this venerable
thrombolytic agent may be coming to an end.
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